Mutual Funds
Mutual Funds
Fund Profile
Scheme Profile
Daily NAV
Historical NAV
Category Returns
Dividend Details
Fund Ranking
MF Activities
All Holdings
What's In / What's Out
MF Trends
MF Tools
  Home   >   MUTUAL FUND  >  MUTUAL FUNDS  >  CATEGORY RETURNS
CATEGORY RETURNS      
AMC : Category : Scheme :
Nippon India Nifty Pharma ETF
TypeInvestment In% of NAVNo. of sharesValue (Rs cr)
Domestic EquitiesSun Pharmaceutical Industries Limited23.16871307923239.5592
Domestic EquitiesCipla Limited10.3396698160106.9092
Domestic EquitiesDivi's Laboratories Limited9.8754157649102.1093
Domestic EquitiesDr. Reddy's Laboratories Limited9.206175619495.1897
Domestic EquitiesLupin Limited6.047730031762.5320
Domestic EquitiesLaurus Labs Limited4.810448227149.7390
Domestic EquitiesTorrent Pharmaceuticals Limited4.672712985748.3146
Domestic EquitiesAurobindo Pharma Limited4.118734716542.5867
Domestic EquitiesAlkem Laboratories Limited3.84226988139.7273
Domestic EquitiesGlenmark Pharmaceuticals Limited3.515018674436.3441
Domestic EquitiesMankind Pharma Limited3.051814018031.5545
Domestic EquitiesBiocon Limited2.872374556329.6995
Domestic EquitiesZydus Lifesciences Limited2.825931002229.2196
Domestic EquitiesIPCA Laboratories Limited2.425317257625.0770
Domestic EquitiesAbbott India Limited1.8883649219.5247
Domestic EquitiesJB Chemicals & Pharmaceuticals Limited1.731610108017.9043
Domestic EquitiesGland Pharma Limited1.68079876217.3782
Domestic EquitiesPiramal Pharma Limited1.388876703614.3597
Domestic EquitiesAjanta Pharma Limited1.29425225513.3815
Domestic EquitiesWockhardt Limited1.224010247612.6558
Total 99.9793 1033.7659
Cash & Cash Equivalents and Net AssetsTriparty Repo0.0316 0.3267
Cash & Cash Equivalents and Net AssetsCash Margin - CCIL0.0000 0.0005
Cash & Cash Equivalents and Net AssetsNet Current Assets-0.0110 -0.1134
Total 0.0207 0.2138
 
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.